ReviewMediterranean journal of hematology and infectious diseases2018
Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy.
Review in Mediterranean journal of hematology and infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry.Haematologica · 2025Article
- Innate lymphoid cells in bone marrow and peripheral blood of healthy individuals and in bone marrow of patients with myelodysplastic syndromes.Frontiers in immunology · 2025Article
- Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes.Seminars in hematology · 2024Review
- Tuberculosis-induced aplastic crisis and atypical lymphocyte expansion in advanced myelodysplastic syndrome: A case report and review of literature.World journal of clinical cases · 2023Article
- Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2023Review
- Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire: The MINDSET study.European journal of haematology · 2022Article
- Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes.EJHaem · 2022Article
- The Possible Role of Chronic Infection in the Etiopathogenesis of a Case of 5q-Syndrome Associated with Tuberculosis and Abnormality of the X Chromosome.Mediterranean journal of hematology and infectious diseases · 2022Article
- De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences.Mediterranean journal of hematology and infectious diseases · 2022Review
- Article
- Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents.Therapeutic advances in hematology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections remain a significant problem in myelodysplastic syndromes (MDS) in treated as well in non-treated patients and assume a particular complexity. The susceptibility to infections is due, in the absence of intensive chemotherapies, mainly to functional defects in the myeloid lineage with or without neutropenia. Furthermore, MDS includes a heterogeneous group of patients with very different prognosis, therapy and risk factors regarding survival and infections. You should distinguish risk factors related to the disease, like as neutrophils function impairment, neutropenia, unfavorable cytogenetics and bone marrow insufficiency; factors related to the patient, like as age and comorbidities, and factors related to the therapy. When the patients with MDS are submitted to intensive chemotherapy with and without hematopoietic stem cell transplantation (HSCT), they have a risk factor for infection very similar to that of patients with acute myeloid leukemia (AML), and mostly related to neutropenia. Patients with MDS treated with supportive therapy only or with demethylating agent or lenalidomide or immunosuppressive drugs should have a tailored approach. Most of the infections in MDS originate from bacteria, and the main risk factors are represented by neutropenia, thrombocytopenia, and unfavorable cytogenetics. Thus, it is reasonable to give antibacterial prophylaxis to patients who start the therapy with demethylating agents with a number of neutrophils <500 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.